OP24.02: Combination of use of dienogest with LNG IUD Mirena

Currently the LNG IUD Mirena is widely used for the purpose of treatment of metrorrhagia, endometrial hyperplasia and adenomyosis. In recent years, duet introduction of 3D US into clinical practice, the research, aimed at identification of IUD expulsion risk factors came forward. We established, that expulsion risk factors are extended area of uterine cavity (S) >9 cm2 associated with increase of distance between tubal angles (L) >4,5 cm. In certain cohort of patients application of Mirena due to a range of causes including compliance in case of necessity of long-term application is preferable. Another widely used medication for treatment of same pathologies is dienogest. 25 patients with previous expulsions of IUD with uterine cavity area >9 cm2 (in the average12,46±1,96 cm2), distance between tubal angles > 4,5 cm (in the average4,98±0,42 cm), dienogest was prescribed 2mg daily during 6 months, after which patients underwent 3D US again. Ultrasound transformation of myometrium and uterine cavity parameters after 6 months of Visanne administration in 18 (72%) patients was expressed by reduction of the uterine cavity area in the average down to 7,87±0,61cm2 and reduction of distance between tubal angles in the average down to 4,04±0,10 cm. These patients had Mirena introduced again. During 12 months of observation after its introduction no cases of Mirena expulsion were identified. Supporting information can be found in the online version of this abstract Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.